AstraZeneca

Official website ↗

AstraZeneca plc (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Its British counterpart, Zeneca PLC, was formed in 1993 when ICI divested its pharmaceuticals businesses; Astra AB and Zeneca PLC merged six years later, with the chosen headquarters in the United Kingdom. AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also secondary listings on Nasdaq Stockholm and the New York Stock Exchange. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide.

Source: https://www.astrazeneca.com/our-company.html

acalabrutinibCalquence

Calquence (acalabrutinib) is a selective Bruton tyrosine kinase (BTK) inhibitor from AstraZeneca. By locking BTK, it cuts the survival and multiplication signal that malignant B cells rely on, and is used in chronic lymphocytic leukaemia and mantle cell lymphoma, alone or with antibody-based combinations.

Acalabrutinib is a targeted medicine called a BTK inhibitor. In CLL and mantle cell lymphoma, the cancerous B cells keep receiving stay-alive and mult

benralizumabFasenra

interleukin-5 receptor alpha-directed cytolytic monoclonal antibody

Benralizumab (Fasenra) is a biologic medicine that targets eosinophils, a type of white blood cell that drives certain kinds of inflammation. It binds to the interleukin-5 receptor on eosinophils and recruits natural killer cells to remove them. It is used as add-on treatment for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.

Benralizumab is an antibody that attaches to a receptor called IL-5Rα found on the surface of eosinophils. Once it binds, it also grabs the attention

budesonide/formoterolSymbicort

inhaled corticosteroid and long-acting beta-2 agonist combination

Symbicort combines budesonide and formoterol in a single inhaler from AstraZeneca for the regular treatment of asthma and chronic obstructive pulmonary disease (COPD). Budesonide calms inflammation in the airways, while formoterol keeps the muscles around the airways relaxed for up to 12 hours.

Budesonide and formoterol are two medicines in one inhaler that work together on the airways. Budesonide is an inhaled corticosteroid that reduces swe

dapagliflozinFarxiga

SGLT2 inhibitor

Farxiga (dapagliflozin) is an SGLT2 inhibitor from AstraZeneca. It makes the kidneys excrete extra glucose, lowering blood sugar in type 2 diabetes, and it also protects against heart failure hospitalisation in people with diabetes and cardiovascular risk.

The kidneys filter blood continuously and normally reclaim all the glucose so none is lost in urine. Dapagliflozin blocks SGLT2, the transporter respo

durvalumabImfinzi

PD-L1 checkpoint inhibitor

Imfinzi (durvalumab) is a PD-L1 checkpoint inhibitor from AstraZeneca. By lifting the PD-L1 brake on T cells it restores immune attack on cancer, and is used around surgery in resectable lung cancer and after chemoradiation or chemotherapy in other lung cancer settings.

T cells are designed to kill abnormal cells, but cancers protect themselves by displaying PD-L1, which binds the PD-1 off-switch on T cells. Durvaluma

olaparibLynparza

Lynparza (olaparib) is an oral PARP inhibitor from AstraZeneca for selected BRCA-mutated or homologous recombination-deficient cancers of the ovary, breast, pancreas, and prostate. It blocks DNA repair enzymes that cancer cells depend on, so damaged cancer cells die while treatment helps keep responding cancers from returning.

Olaparib blocks PARP, an enzyme cells use to repair single-strand DNA breaks. When PARP is inhibited, breaks accumulate. Cancer cells that already car

omeprazolePrilosec

proton pump inhibitor

Omeprazole (Prilosec) is a proton pump inhibitor that reduces the amount of acid the stomach makes. It treats frequent heartburn over the counter, and by prescription it is used for gastroesophageal reflux disease, acid-related ulcers, and conditions with excess stomach acid.

Omeprazole belongs to the proton pump inhibitor class. After it is absorbed, it reaches the acid-producing parietal cells of the stomach and forms a s

osimertinibTagrisso

third-generation EGFR tyrosine kinase inhibitor

Tagrisso (osimertinib) is an oral, mutant-selective EGFR inhibitor from AstraZeneca for non-small cell lung cancer carrying activating EGFR mutations. It is used after surgery, after chemoradiation, as first-line therapy for advanced disease, and against the T790M resistance mutation.

Certain lung cancers depend on mutated forms of EGFR, a receptor that tells cells to grow. Osimertinib is taken by mouth and binds irreversibly to the

quetiapineSeroquel

atypical antipsychotic

Seroquel (quetiapine) is an atypical antipsychotic used for schizophrenia, manic and depressive episodes of bipolar I disorder, and as add-on treatment in major depressive disorder. It modulates dopamine and serotonin receptors, calming overactive signaling in mood and thought circuits.

Quetiapine is an atypical antipsychotic that works on several chemical messengers in the brain, especially dopamine and serotonin. In conditions like

ticagrelorBrilinta

P2Y12 platelet inhibitor

Brilinta (ticagrelor) is a P2Y12 platelet inhibitor from AstraZeneca that prevents platelets from clumping into clots. It reduces heart attack and stroke risk in high-risk coronary artery disease and after acute coronary syndromes or myocardial infarction, and lowers stroke risk after minor ischemic stroke or high-risk TIA.

Ticagrelor belongs to the antiplatelet class. It blocks the P2Y12 receptor on platelets, a key signal that makes platelets collect and stick together.